Serum neurofilament light-chain (sNfL) levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis (RRMS) patients in the CombiRx trial

被引：0
|
作者：
Cutter, Gary [1 ]
Rudick, Richard A. [2 ]
De Moor, Carl [2 ]
Singh, Carol M. [2 ]
Fisher, Elizabeth [2 ]
Lublin, Fred D. [3 ,4 ]
Wolinsky, Jerry S. [5 ]
McFarland, Henry [6 ]
Jacobson, Steven [7 ]
Naylor, Maria L. [2 ]
机构：
[1] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA
[2] Biogen, Cambridge, MA USA
[3] Icahn Sch Med Mt Sinai, Dept Neurol, Corinne Goldsmith Dickinson Ctr Multiple Scleros, New York, NY 10029 USA
[4] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA
[5] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
[6] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA
[7] Natl Inst Neurol Disorders & Stroke, Viral Immunol Sect, NIH, Bethesda, MD USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2410
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15
    Kappos, Ludwig
    Kuhle, Jens
    Multanen, Juha
    Kremenchutzky, Marcelo
    di Cantogno, Elisabetta Verdun
    Cornelisse, Peter
    Lehr, Lorenz
    Casset-Semanaz, Florence
    Issard, Delphine
    Uitdehaag, Bernard M. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11): : 1202 - 1207
  • [42] Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis
    Engel, Sinah
    Protopapa, Maria
    Steffen, Falk
    Papanastasiou, Vakis
    Nicolaou, Christoforos
    Protopapas, Michalis
    Zipp, Frauke
    Bittner, Stefan
    Luessi, Felix
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [43] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Saida, Takahiko
    Hao, Qi
    Kanda, Michihiro
    Tani, Yumiko
    BMC NEUROLOGY, 2023, 23 (01)
  • [44] Uric acid serum levels in patients with relapsing-remitting multiple sclerosis in Iran
    Ashtari, F.
    Aghaei, M.
    Bahar, M. A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S63 - S63
  • [45] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Takahiko Saida
    Qi Hao
    Michihiro Kanda
    Yumiko Tani
    BMC Neurology, 23
  • [46] Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
    Thebault, Simon
    Abdoli, Mohammad
    Fereshtehnejad, Seyed-Mohammad
    Tessier, Daniel
    Tabard-Cossa, Vincent
    Freedman, Mark S.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [47] Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
    Simon Thebault
    Mohammad Abdoli
    Seyed-Mohammad Fereshtehnejad
    Daniel Tessier
    Vincent Tabard-Cossa
    Mark S. Freedman
    Scientific Reports, 10
  • [48] Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study
    Kizilay, Tugce
    Akbayir, Ece
    Erol, Ruziye
    Demir, Ayca Simay
    Yasargun, Duygu Ozkan
    Yilmaz, Vuslat
    Tuzun, Erdem
    Turkoglu, Recai
    EUROPEAN NEUROLOGY, 2024, 87 (04) : 203 - 210
  • [49] Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
    Lewis, Ariane
    Galetta, Steven
    NEUROLOGY, 2022, 98 (11) : 470 - 470
  • [50] Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis
    Bridel, Claire
    Killestein, Joep
    Teunissen, Charlotte
    NEUROLOGY, 2022, 98 (11) : 471 - 471
12345